An interesting justification for the target price, considering that when deals are announced, they are announced, and they cannot be predicted in advance. Once a good deal for the clinical side is pushed through the pipeline, it will validate the demand side quite nicely in one fell swoop.
But targets have to follow the share price level, that’s clear, hence the downward adjustment.
3 Likes